Lucence Diagnostics
Lucence Liquid Biopsy Test to Receive Medicare Reimbursement in Lung Cancer
Lucence's amplicon-based LiquidHallmark liquid biopsy assay will now be covered under a finalized local coverage determination from Medicare contractor Palmetto.
Lucence Taps Omnigen to Distribute Liquid Biopsy Tests in Turkey
The Istanbul-based medical test and device distributor will market Lucence's liquid biopsy tests, including its NGS assay LiquidHallmark, to hospitals and physicians in the region.
Lucence Publishes Clinical Validation of LiquidHallmark Circulating Tumor DNA Test, Expands to RNA
Premium
The firm plans to ramp up US commercialization following the study, while continuing to develop its cell-free RNA diagnostic platform.
Lucence, Veterans' Affairs Health Care System Launch Liquid Biopsy Screening Study
The study will evaluate the feasibility of screening high-risk lung cancer patients with Lucence's LiquidHallmark assay.
Researchers used the amplicon-based LiquidHallmark test to correlate tumor DNA changes with treatment response.
Dec 10, 2020
Lucence Obtains CLIA Certification for Palo Alto Lab
Jan 27, 2020
Nov 19, 2019